Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Equine Vet J ; 51(5): 612-616, 2019 Sep.
Article in English | MEDLINE | ID: mdl-30560998

ABSTRACT

BACKGROUND: There is a large body of evidence supporting bovine papillomavirus types 1 and 2 (BPV1; BPV2) as aetiological agents of equine sarcoids. However, there is conflicting data regarding BPV1/2 infection in sarcoid-free equids. OBJECTIVES: Data obtained between 2007 and 2017 by BPV1/2 screening of sarcoids and nonsarcoid tumours vs. samples from healthy equids are presented to help clarify this issue. STUDY DESIGN: Cross-sectional study. METHODS: Tumour material obtained from horses, donkeys and mules with confirmed sarcoids (n = 130), suspected sarcoids (n = 120), or nonsarcoid lesions (n = 70), skin biopsies from 102 tumour-free horses and dandruff/hair roots from 35 tumour-free donkeys and mules were screened for BPV1/2 infection. Sample DNA was extracted and validated by equine ß-actin PCR. BPV1/2 screening was performed by BPV1/2 E5-specific PCR allowing for the detection of less than 10 viral DNA molecules. Twenty-six amplicons were bidirectionally sequenced and compared to known E5 variants using BLAST program. RESULTS: BPV1/2 E5 PCR scored positive for 130/130 diagnosed sarcoids, 63/120 suspected sarcoids and 13/70 nonsarcoid lesions, whereas 137/137 DNA aliquots derived from tumour-free equids tested negative. On predicted E5 protein level, six different BPV1 E5 variants were identified. MAIN LIMITATIONS: The diagnosis of equine sarcoid was not confirmed in 120 lesions. CONCLUSIONS: Lack of BPV1/2 E5 DNA in tumour-free equids and the prevalence of sarcoid disease in young adult individuals suggest that the time span between initial infection and sarcoid development is short. This contrasts with the long phase of virus latency characterising infection of humans by carcinogenic papillomaviruses. Presence of BPV1/2 DNA in several cases of poor wound healing/hypergranulation and dermatitis points to these skin disorders being possibly co-induced by BPV1/2. PCR screening of tumour tissue/scrapings for BPV1/2 DNA represents a reliable tool for the rapid validation of a clinical diagnosis of equine sarcoid.


Subject(s)
Bovine papillomavirus 1/isolation & purification , Equidae/virology , Papillomavirus Infections/veterinary , Skin Neoplasms/veterinary , Animals , Case-Control Studies , Papillomavirus Infections/virology , Retrospective Studies , Skin Neoplasms/virology
2.
Vet J ; 225: 3-8, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28720295

ABSTRACT

In horses, squamous cell carcinomas (SCC) commonly affect the external genitals. There is growing evidence that equine papillomavirus type 2 (EcPV2) infection promotes disease development. To assess the possible association of EcPV2 with equine SCCs of the head (HSCC), 15 HSCC DNA samples were screened by E6/E7, E2, and LCR PCR and amplicons were analysed for sequence variations. The physical form of EcPV2 in HSCC, genital lesions, and smegma from horses with SCC was then addressed using EcPV2 immunocapture PCR (IC/PCR) for detection of virion, and E6 vs. E2 qPCR to investigate possible integration events. Four of 15 HSCC tested positive for EcPV2 DNA and harboured known or novel genetic variants of E6, E7, E2 and the LCR. Eighteen of 35 sample extracts including 3/4 smegma samples scored positive by IC/PCR, suggesting that about 51% of tested extracts harboured virions. E6/E2 qPCR from tumour DNA revealed E2/E6 copies/cell ranging between <1 (E2; E6) and 797 (E2) or 1434 (E6). IC/PCR-positive smegma samples contained higher E2 and E6 copy numbers, ranging between 1490 and 4.95×105 (E2) or 2227 and 8.54×105 (E6) copies/cell. Together with IC/PCR results, this finding suggests that smegma can serve as a rich EcPV2 reservoir. HSCCs harboured significantly lower viral DNA amounts (<1-25 copies/cell) than most genital tumour and smegma DNA isolates. The majority of samples contained more E6 than E2 DNA, with E6:E2 ratios ranging between 0.88 and 4.12. Although not statistically significant (P>0.05), this finding suggests that EcPV2 can integrate into the equine host cell genome.


Subject(s)
Carcinoma, Squamous Cell/veterinary , Horse Diseases/virology , Human papillomavirus 16 , Papillomaviridae , Papillomavirus Infections/veterinary , Animals , Carcinoma, Squamous Cell/virology , DNA, Viral/analysis , Disease Reservoirs/veterinary , Female , Head and Neck Neoplasms/veterinary , Head and Neck Neoplasms/virology , Horses , Human papillomavirus 16/genetics , Humans , Male , Papillomaviridae/genetics , Polymerase Chain Reaction/veterinary , Smegma/virology
3.
J Dent Res ; 83(6): 491-5, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15153458

ABSTRACT

Lysophosphatidic acid (LPA) is a locally produced bioactive phospholipid which is involved in tissue repair. The objective of this study was to determine whether dental pulp tissue also responds to the phospholipid. Effects of LPA on proliferation, differentiation, and mitogen-activated protein kinase (MAPK) signaling of dental pulp fibroblasts (DPF) were examined in vitro. We report that DPF express LPA receptors LPA1, LPA2, and LPA3 and respond to the ligand with increased mitogenic activity. Involvement of extracellular signal-regulated kinase, p38 MAPK, and c-Jun NH(2)-terminal kinase in LPA signaling could be demonstrated by use of specific inhibitors and detection of the phosphorylation status of the kinases. An increased mitogenic activity paralleled a decreased number of alkaline-phosphatase-positive cells and expression levels of dentin sialophosphoprotein and osteocalcin. Together, these results suggest that dental pulp fibroblasts can respond to LPA, a process that may play a role in pulp tissue repair.


Subject(s)
Dental Pulp/drug effects , Fibroblasts/drug effects , Lysophospholipids/pharmacology , Adult , Alkaline Phosphatase/analysis , Biomarkers/analysis , Cell Differentiation/drug effects , Cell Division/drug effects , Cells, Cultured , Dental Pulp/cytology , Extracellular Matrix Proteins , Fibroblasts/cytology , Humans , JNK Mitogen-Activated Protein Kinases , MAP Kinase Signaling System/drug effects , Middle Aged , Mitogen-Activated Protein Kinases/analysis , Osteocalcin/analysis , Phosphoproteins/analysis , Phosphorylation , Protein Precursors/analysis , Receptors, G-Protein-Coupled/analysis , Receptors, Lysophosphatidic Acid , Sialoglycoproteins/analysis , p38 Mitogen-Activated Protein Kinases
4.
Int Endod J ; 37(2): 145-50, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14871182

ABSTRACT

AIM: To examine the involvement of mitogen-activated protein kinases (MAPK) signalling on thrombin-stimulated human dental pulp fibroblasts (DPF). METHODOLOGY: Dental pulp fibroblasts were isolated from dental pulp connective tissue of third molars and expanded in vitro. Expression of thrombin receptors was analysed by RT-PCR, and cell proliferation was measured by 3[H]-thymidine incorporation assay. Phosphorylation levels of MAPK were determined by Western blot analysis, and alkaline phosphatase activity was measured to serve as a marker for odontogenic differentiation. Statistical analysis was performed by Student's t-test. RESULTS: Dental pulp fibroblasts express the thrombin receptors protease-activated receptor-1 (PAR-1), PAR-3 and PAR-4. Measurement of 3[H]-thymidine incorporation revealed a dose-dependent increase of DNA synthesis in response to thrombin treatment. The thrombin-induced mitogenic activity was decreased by the extracellular signal-regulated protein kinase (ERK) signalling inhibitor PD98059 (P < 0.05), and by SB203580 (P < 0.05), a p38 MAPK inhibitor. Western blot analysis demonstrated increased phosphorylation of ERK in DPF following stimulation with thrombin, while p38 MAPK and c-Jun NH2-terminal kinase (JNK) were not activated. Alkaline phosphatase activity of DPF remained unchanged upon incubation with thrombin. CONCLUSIONS: These results suggest that signalling via MAPK mediates the mitogenic activity of thrombin on DPF and may thus play a role during the early stages of pulp repair.


Subject(s)
Dental Pulp/drug effects , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/physiology , Receptors, Thrombin/biosynthesis , Thrombin/pharmacology , Adult , Blotting, Western , Cell Division/drug effects , Cells, Cultured , Dental Pulp/cytology , Dental Pulp/enzymology , Fibroblasts/drug effects , Fibroblasts/enzymology , Humans , Middle Aged , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/metabolism , Phosphorylation , RNA/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Thrombin/physiology , p38 Mitogen-Activated Protein Kinases
SELECTION OF CITATIONS
SEARCH DETAIL